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Present Alzheimer’s disease (AD) therapies suffer from inefﬁcient effects on AD symptoms
like memory or cognition, especially in later states of the disease. Used acteylcholine
esterase inhibitors or the NMDA receptor antagonist memantine address one target
structure which is involved in a complex, multifactorial disease progression. So the beneﬁt
for patients is presently poor. A more close insight in the AD progression identiﬁed more
suggested target structures for drug development. Strategies of AD drug development
concentrate on novel target structures combined with the established ones dedicated
for combined therapy regimes, preferably by the use of one drug which may address
two target structures. Protein kinases have been identiﬁed as promising target structures
because they are involved in AD progression pathways like pathophysiological tau protein
phosphorylations and amyloid β toxicity.The reviewarticlewill shortly viewearly inhibitors of
single protein kinases like glycogen synthase kinase (gsk3) β and cyclin dependent kinase
5. Novel inhibitors will be discussed which address novel AD relevant protein kinases
like dual-speciﬁcity tyrosine phosphorylation regulated kinase 1A (DYRK1A). Moreover,
multitargeting inhibitors will be presented which target several protein kinases and those
which are suspected in inﬂuencing other AD relevant processes. Such a multitargeting is
the most promising strategy to effectively hamper the multifactorial disease progression
and thus gives perspective hopes for a future better patient beneﬁt.
Keywords: protein kinase, inhibitor, tau phosphorylation, small molecules, structure–activity relationships,
inhibitor binding
INTRODUCTION
Presently Alzheimer’s disease (AD) therapies are limited by the
availability of just two groups of drugs with one group consist-
ing of just one drug. Acetylcholine esterase inhibitors increase the
neuronal acetylcholine amounts, whereas memantine, an antag-
onist at the neuronal N-methyl D-aspartate (NMDA) receptor,
reduces a neuronal overstimulation caused by the neurotransmit-
ter glutaminic acid (Birks, 2006; McShane et al., 2006). Both the
loss of acetylcholine and the neuronal overstimulation contribute
to the decay of neurons and thus the AD progression. However,
the patient beneﬁt of the present drugs is poor and limited to the
early stage of the disease (Terry and Buccafusco, 2003; Raina et al.,
2008). Memory, cognition, and daily behavior for life managing is
hardly improved by the drugs in later stages of a severe AD (Terry
and Buccafusco, 2003; Raina et al., 2008). It is known that AD is
a multifactorial disease which means that different pathophysi-
ological factors all contribute to the AD progression (Iqbal and
Grundke-Iqbal, 2002). Most important hallmarks are the pro-
tein deposites which are found inside and outside the neuronal
cells, namely the extracellular Aβ plaques and the intracellular
neuroﬁbrillary tangles (NFTs; Mohandas et al., 2009; Piau et al.,
2011).
However, both proteins and their precursors are known to play
a central role in the neuronal decay and disease progression. While
a toxicity of the Aβ plaques is still under debate, their soluble pre-
cursors of non-aggregated Aβ proteins are toxic in various ways
also by the formation of NFTs as a result of aggregation of a hyper-
phosporylated and misfolded tau protein as will be discussed later
(Mattson, 2004; Pakaski and Kalman, 2008; Mohandas et al., 2009;
Piau et al., 2011). Such tau protein can no longer support the
intracellular transport mediated by the microtubules and with the
loss of neuronal function the cell is dedicated to undergo apop-
tosis (Iqbal and Grundke-Iqbal, 2008; Marco et al., 2010). Protein
kinases are known to mainly contribute to these toxic events as
they play a central role in the cellular pathways of regulated cell
function and division.
With the understanding of various protein kinase functions
the question of developing inhibitors as potential AD therapeutics
has arisen. Protein kinase inhibitors are long established in cancer
therapies where they regulate the overactivity of protein kinases
which lead to uncontrolled cell divisions, cell migration, and cel-
lular invasion (Krug and Hilgeroth, 2008; Zhang et al., 2009). The
toxicity of such anticancer protein kinase inhibitors has always
been a critical question of causing toxic or undesired side-effects
(Liao and Andrews, 2007). Viewing the years of research in this
ﬁeld multitargeting protein kinase inhibitors established and are
well tolerated by patients with only limited side-effects (Krug and
Hilgeroth, 2008). So there are certain perspectives that protein
kinase inhibitors forAD therapymay showpromising effects in the
pathophysiological AD process on one hand and for a more effec-
tive therapy on the other hand with respect to the knowledge that
present drugs are no real perspective drugs to effectively inﬂuence
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the disease progression. The review will give a short summary
of the early protein kinase inhibitors which target early known
single target structures. Such early protein kinase inhibitors have
been developed to reduce the activity of tau protein hyperphos-
phorylating kinases which have been found partly overactive or
overexpressed in respective neuronal cells in AD brains and thus
mainly contribute to the aggregation and loss of function of the
hyperphosphorylated tau. Then novel inhibitors will be viewed
which address novel targets with evidence for the AD progression
and those which are dedicated to a multitargeting of more than
one target structure.
EARLY PROTEIN KINASE INHIBITORS
Tau protein has been the main target structure for protein kinase
inhibitors since tau proteinwas found hyperphosphorylated inAD
brains. The tau protein hyperphosphorylation results in dissoci-
ation from the microtubules the function of which is supported
by tau protein (Martin et al., 2013). Moreover, the hyperphospho-
rylation causes a loss of solubility and leads to the formation of
paired helical ﬁlaments (PHFs) which further aggregate to NFTs
(Avila, 2006; Martin et al., 2011, 2013). The reason for the tau pro-
tein hyperphosphorylation is an imbalance of phosphorylation
and dephosphorylation of tau. This imbalance is partly driven by
a reduced tau protein dephosphorylation or by an overactivity of
the phosphorylating protein kinases (Iqbal and Grundke-Iqbal,
2002; Tian and Wang, 2002; Pei et al., 2008; Martin et al., 2013).
Glycogen synthase kinase (GSK) 3β plays a central role in the tau
phosphorylation process. It has been reported that 31% of the
pathological phosphorylation sites of tau protein are phospho-
rylated by GSK3β (Martin et al., 2013). GSK3β has been found
co-localized with NFTs and is found overexpressed in AD brains
with increased activity (Pei et al., 1997; Leroy et al., 2007). Toxic
Aβ is known to increase the activity of GSK3β which contributes
to an increasedAβ production via the tau phosphorylation (Hoshi
et al., 1996; Takashima et al., 1996). Therefore GSK3β forms a link
of Aβ toxicity and tau pathology (Martin et al., 2013). Lithium as
an early GSK3β inhibitor reduced tau phosphorylation and pre-
vented reversed aspects of tau pathology in animal models (Tariot
and Aisen, 2009). However, treatment of AD patients with mild
AD in the early disease states showed no improvement in cogni-
tion (Hampel et al., 2009). The result correlated with unchanged
AD biomarkers in the cerebrospinal ﬂuid (CSF) of the patients,
namely phosphorylated tau, total tau, and toxic Aβ (Hampel et al.,
2009). Several GSK3β inhibitors are under development belonging
to the paullone, indirubin, and the maleimide families. However,
no representative of these inhibitor groups reached clinical tri-
als so far. Reasons for their failure have been proven cytotoxic
effects.
The other important tau protein kinase which is involved
in pathophysiological tau protein phosphorylation is the cyclin
dependent kinase 5 (cdk5). The normally cdk5 regulating pro-
tein p35 is found truncated in AD brains to 25 amino acids. This
protein p25 leads to a constitutive activation of cdk5 and thus
causes the pathophysiological tau phosphorylation (Patrick et al.,
1999). The hyperphosphorylated tau protein dissociates from the
microtubules and forms NFTs on cdk5 induction by p25 (Cruz
et al., 2003; Noble et al., 2003). Also NFTs are phosphorylated
by cdk5 action (Baumann et al., 1993; Hollander et al., 1996).
Cdk5 phosphorylated tau becomes a better substrate for GSK3β
so that excessive tau phosphorylation proceeds (Sengupta et al.,
1998). Moreover, cdk5 promotes apoptosis in AD brains which
may followAβ toxicity inﬂuenced by the hyperphosphorylated tau
or by remaining p35 protein (Hamdane et al., 2005; Utreras et al.,
2009).
From the number of cdk inhibitors whichwere all non-selective
like ﬂavoperidol a pan-cdk inhibitor investigated for cancer ther-
apy, cdk5-selective so-called CP-inhibitors were reported with
nanomolar afﬁnities and the ability to cross the blood brain bar-
rier (Wen et al., 2008). They were described to reduce increased
Aβ levels on p25 overexpression. However, as far as known these
inhibitors remained in preclinical states.
NOVEL INHIBITORS
SINGLE PROTEIN KINASE TARGETING OF CDK5, P38, JNK, Erk, CK, and
DYRK1A
Due to the signiﬁcant role of cdk5 in tau phosphorylation there
have been ongoing efforts to develop novel inhibitors of the kinase
whichhave been structurally basedon the cdk inhibitor roscovitine
(seliciclib) as a trisubstituted purine compound (Figure 1).
Beside cdk5 roscovitine inhibits several cdks like cdk1, cdk2,
or cdk9 in micromolar concentrations (Bettayeb et al., 2008). It
presently undergoes clinical trials of various types of cancer (U.S.
National Institutes of Health, 2010). However, roscovitine crosses
the blood brain barrier and this advantage might have driven fur-
ther studies because only about 2% of small molecule inhibitors
are able to penetrate into the CNS (Meijer and Raymond, 2003;
Pardridge, 2005). One structurally varied compound has been
DRF 53 with a 2-pyridyl residue attached to the 4-position of
the benzylamine substituent. With a similar cdk inhibition pro-
ﬁle the toxic properties increased compared to roscovitine so that
it is suggested to be used as anticancer agent like roscovitine
(Bettayeb et al., 2008). In a recent paper the 2-pyridyl residue has
been changed by both a 3- and a 4-pyridyl residue (Demange
et al., 2013). More favourable cdk5 inhibition data resulted in
nanomolar ranges. Docking studies in the ATP binding pocket
demonstrated a hydrogen bonding of the 4-pyridyl nitrogen to
the Nε of Lys89 of the protein backbone to explain the increased
activity. However, beside cdk5 also cdk2 was inhibited and all
derivatives were toxic (Demange et al., 2013).
P38 protein kinase belonging to the mitogen activated protein
kinases (MAPKs) is a tau protein phosphorylating kinase which
contributes to tau protein dissociation from the microtubules and
facilitates a further tau aggregation (Martin et al., 2013). In AD
brains Aβ activates p38 isoforms p38α und p38β via activated glia
(Rojo et al., 2008). In the following proinﬂammatory cytokines are
produced like interleukin-1β (IL-1β) and tumor necrosis factor α
(TNFα) (Shaftel et al., 2008). So nanomolar active p38 inhibitor
SB-239063 is able to reduce the inﬂammatory cytokine production
(Underwood et al., 2000).
Erk isoforms 1 and 2 contribute to abnormal tau protein
phosphorylation including the formation of pathological tau con-
formations (Pei et al., 2002; Martin et al., 2013). So the inhibition
of Erk promises a reduced tau pathology. FR-180204 is the sole
selective Erk inhibitor described so far (Ohori et al., 2005).
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 189 | 2
“fncel-07-00189” — 2013/11/18 — 16:05 — page 3 — #3
Tell and Hilgeroth AD-relevant protein kinase inhibitors
FIGURE 1 | Single protein kinase-targeting inhibitors.
Finally, JNKs of the MAPK family have been interesting target
structures because they also contribute to tau phosphorylation.
JNK activation is mediated by toxic Aβ fragments (Philpott and
Facci, 2008). However, activated JNKs also increase the γ-secretase
activity and thus contribute to increased toxic Aβ levels resulting
from the amyloid precursor protein (APP) by γ-secretase cleav-
age (Shen et al., 2008). Both MAPKs p38 and JNK have been
co-puriﬁed with NFTs in AD brains (Zhu et al., 2000). So JNKs are
potential AD-therapeutic target structures. SP-600125 is a potent
JNK isoform inhibitor (Bennett et al., 2001). However, JNK3 is the
known isoform which mediates the toxic response to Aβ with a
greater role in the regulation of toxicity in brain than the other
isoforms JNK1/2 (Philpott and Facci, 2008). So it would be of
beneﬁt to develop a more exclusive JNK3 inhibitor.
Casein kinase isoforms CK1δ and CK1ε are expressed in brain
and are mainly involved in the pathophysiological tau phosphory-
lationwith 26%of those tau amino acids beingphophorylatatedby
CK1 (Knippschild et al., 2005; Martin et al., 2013). CK1δ mRNA
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levels as well as the kinase itself are found mainly increased in
AD brains up to 30-fold (Yasojima et al., 2000). CK1 has been
found co-localized with NFTs like GSK3β being active in the
tau phosphorylation of NFTs (Kuret et al., 1997; Schwab et al.,
2000). Moreover, CK phosphorylation of tau sites facilitates the
dissociation from the microtubules (Martin et al., 2013). Sim-
ilar to GSK3β Aβ peptides activate CK thus triggering the tau
pathology which on the other hand increases Aβ (Takashima et al.,
1996; Flajolet et al., 2007). Furthermore, CK1ε is known to play
a role in the APP processing, likely by regulating the activity
of γ-secretase which contributes to the formation of the toxic
Aβ peptides. CK is additionally a priming kinase for GSK3β
and has a regulatory role in cdk5 function (Knippschild et al.,
2005).
Thus, CK is an interesting target structure for AD relevant pro-
tein kinase inhibitors, because the AD overactivity of the kinase
maybe regulatedby an inhibitorwithout effecting the basic activity
in cells. The presently known CK inhibitors IC-261 and tetrabro-
mocinnamic acid (TBCA) are poor inhibitors with activities in
partly higher micromolar ranges (Mashhoon et al., 2000; Pagano
et al., 2007).
Dual-speciﬁcity tyrosinephosphorylation-regulating kinase 1A
(DYRK1A) phosphorylates tau and transcription factor cAMP
Response Element Binding (CREB) which is involved in learning
and memory (Yang et al., 2001). Aβ peptides increase DYRK1A
mRNA levels in AD brains (Kimura et al., 2007). However, tau
phosphorylation of DYRK1A is reported to be triggered by GSK3β
(Kimura et al., 2007). Interestingly, DYRK1A phosphorylates
serine 202 of tau protein and this phosphorylation induces a con-
formational change of tau which is pathological (Martin et al.,
2013). Thus, DYRK1A emerged to an interesting protein kinase
for a tau-directed therapy. Harmine is an early DYRK1A inhibitor
which inhibits not only the enzyme itself but also its tyrosine
autophosphorylation (Seifert et al., 2008). While harmine is a
promising inhibitor with activities in nanomolar ranges, recent
structural changes in the molecular skeleton by replacing the
indole nitrogen by an oxygen or a sulfur atom and by replacing the
annelated pyridine in the β-carboline scaffold by a pyrimidine led
to decreases in activity (Loidreau et al., 2013). Moreover, it remains
of doubt whetherDYRK1A is a favourable target kinase because an
inhibition would have negative consequences for the CREB phos-
phorylation. This phosphorylation is necessary for learning and
memory processes which are both impaired in AD patients.
MULTITARGETING
One GSK3β inhibitor named tideglusib (NP-12) with a thiadia-
zolidinone scaffold presently undergoes phase 2 of clinical trials
(Figure 2).
In contrast to the other GSK3β inhibitors which are com-
petitive inhibitors of ATP in the ATP-binding pocket NP-12
is a non-competitive inhibitor which was reported to reduce
tau phosphorylation and amyloid depositions in brain and
prevent neuronal death and cognitive deﬁcits in animal mod-
els (http://clinicaltrials.gov/ct2/results?/term = Noscira, 2010).
Moreover,NP-12was identiﬁed as nuclear receptor PPARγ agonist
which mediated effective anti-inﬂammatory and neuroprotective
properties (Luna-Medina et al., 2007).
In recent studies two inhibitors of the MAPK family have been
investigated in their effects inAβ-injected rats (Ashabi et al., 2012).
U0126 is an inhibitor of MEK1 and 2 which regulates the activity
of Erk1 and 2, while PD169316 is a p38 inhibitor. Aβ activates
MAPKs p38, Erk, and JNK. This activation causes a mitochon-
drial dysfunction by disturbance of the mitochondrial biogenesis.
In early states of AD this mitochondrial abnormality is responsible
for brain energy depletions. Aβ causes deﬁcits in learning,memory
and cognition as demonstrated by the behavioral changes of the
rats afterAβ-treatment. The inhibitor applications led to increased
levels of c-fos as activated gene which contributes to long-term
memory processes. Moreover, the levels of CREB increased. The
transcription factor is not only involved in early processes of long-
term memory as discussed but also regulates the expression of
factors PGC-1α and of NRF-1 (Kudo et al., 2005; Vercauteren
et al., 2006). Both factors play a role in the biogenesis of mito-
chondria which are dysregulated in pathological settings like AD
(Vercauteren et al., 2006). So beside the role of MAPK inhibitors
in a potential tau phosphorylation and tau pathology as discussed
both inhibitors may show beneﬁt for an improvement of memory
and mitochondrial impairment and thus play a neuroprotective
role against Aβ-mediated deﬁcits.
Another MAPK family inhibitor MW01-2-069A of the pro-
tein kinase p38α further proﬁled in Aβ-related studies and
by molecular properties (Munoz et al., 2007). The selectivity
in binding to the p38 isoform α could be reasoned with the
favourable binding of the 4-pyridyl-residue in the ATP binding
pocket which allows hydrogen bonding to the amide function
of Gly110 of the protein backbone. Furthermore, the phenyl
residue ﬁnds an optimized location in the neighbored hydropho-
bic binding pocket. P38α inhibitors have been discussed above
to reduce the production of proinﬂammatory cytokines (Kim
et al., 2004). MW01-2-069A was demonstrated to attenuate Aβ-
mediated decreases of synaptophysin as a presynaptic protein.
The downregulation of synaptophysin causes synaptic dysfunc-
tions in the hippocampus and following hippocampal behavioral
deﬁcits. Favorably, the compound passes the blood brain barrier
and proved to be metabolically stable to an extent of 70% (Munoz
et al., 2007). However, the inhibitory activity in submicromolar
ranges has to be considered critically with respect to later clinical
studies.
The protein kinase Rock has been demonstrated to be activated
in neurites surrounded by amyloid deposites (Petratos et al., 2008).
The following outgrowth of the neurites could be protected by
Rock inhibitor Y-27632. Moreover, an amyloid-induced loss of
synapses could be retracted, so that novel synapse formation were
observed. Furthermore the Rock inhibitor interfered with the APP
processing by an increase of the α-secretase activity leading to less
toxic Aβ (Quin et al., 2006).
1-Aza-9-oxaﬂuorenes discovered as moderate cdk1 inhibitors
ﬁrst have been further developed as selective GSK3β inhibitors
with a 3-carbonyl amide function at the 3-position of the mole-
cular skeleton (Voigt et al., 2008) and a loss of the cdk1 inhibition.
While the pyridine nitrogen atom of the 3-carbonyl derivatives
showed optimized hydrogen bonding to the NH function of
amino acid Val135 of the protein backbone, the NH amide func-
tion bound to carbonyl amide function of Thr138 via a water
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FIGURE 2 | Multitargeting inhibitors.
molecule. Further variations at the molecular scaffold led to the
benzo-annelated lead compounds which further proﬁled as cdk1,
gsk3β and cdk5 inhibitors (Tell et al., 2012a). The binding mode of
those benzo-annelated naphtho compounds to the protein kinase
backbone was demonstrated to be inverse compared to the early 1-
aza-9-oxaﬂuorenes with an orientation of the 3-substituent within
the hydrophobic binding pocket nearby the gatekeeper amino
acids (Voigt et al., 2008; Tell et al., 2012a). One nanomolar active
3-hydroxy compound showed exclusive cdk1, gsk3β and cdk5 inhi-
bition properties and proved to be non-toxic in various cellular
assays (Tell et al., 2012b). It effectively inhibited tau phosphoryla-
tion of various tau amino acids and has been suggested for further
tau pathology studies in tau mice models.
CHALLENGES
During the last decades of AD research it has become more
obvious that AD is not only a multifactorial disease with var-
ious pathological events which contribute to the diseases pro-
gression but also a cross-linked disease. Aβ toxicity has been
demonstrated to increase tau pathology. The linker has been
GSK3β which itself is known to increase the production of
Aβ. GSK3β has been known to be primed by cdk5 so that
the inhibition of cdk5 reduces Aβ toxicity. Synaptic dysfunc-
tions are not only mediated by a decrease of acetylcholine, but
also by Aβ-induced increases of presynaptic proteins. More-
over, Aβ mediates inﬂammatory brain processes via protein
kinases.
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The lowbeneﬁt of drugswhich target one single target structure
enforced studies for a potential multitargeting. The early strategy
in this ﬁeld concentrated on the combination of differently act-
ing drugs by linkers like alkyl chains. The present outcome of
these studies is poor. However, combining of two drugs by a linker
leads to newmolecules with changedmolecular properties. Result-
ing enlarged molecular weights inﬂuence resorption processes and
brain entry properties. It will be a challenge to develop a favourable
combined drug for AD therapy.
Protein kinases have been identiﬁed as mainly disease inﬂu-
encing target structures. Their central role in tau pathology by
tau phosphorylation is extended to disease-linking processes and
makes them to most interesting target structures.
Limits in the development of inhibitors of such AD-relevant
protein kinases have been pointed out: the brain entry of such
small molecules, toxic cellular effects which accompany also recent
inhibitors and highly active molecules. The latter aspect became
obvious by recent studies with GSK3β inhibitors. None of the
highly active inhibitors reached clinical trials. A micromolar
inhibitor seems to be more promising.
What can be the conclusion from all these points? It will be
of great interest to develop a drug which itself has such mul-
titargeting properties. As protein kinases are promising target
structures further developments shall concentrate on a multitar-
geting protein kinase inhibitor which has to be proﬁled in the
various ways like brain entry abilities, low cellular toxicity and
ﬁnally a sufﬁcient but not a too strong activity just to regu-
late the protein kinases’ overactivities and not to interfere with
their activities in normal cells. 1-Aza-9-oxaﬂuorenes from a really
perspective compound class on this way of a hopeful AD drug
development.
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